Smallest saleable patent-practicing unit in life sciences disputes
In this article titled “Smallest saleable patent-practicing unit in life sciences disputes,” author Erin McDermott examines methods for calculating damages in...
CRA has assisted clients in intellectual property (IP) matters concerning products and services in the life sciences sector, including Hatch-Waxman and BPCIA matters. We have also addressed patent, trademark, and copyright infringement, trade secret misappropriation, and IP licensing. Our experts have quantified damages based on lost profit and reasonable royalty methods and provided opinions on irreparable harm. In addition, we have experience addressing other forms of relief, such as rescission and disgorgement.
Our understanding of the unique dynamics of different therapeutic areas informs assessments of commercial success as a secondary indicator of non-obviousness and the claimed nexus between patented technologies and product success.
Engagements
- 01AAA dispute in commercially reasonable efforts to market a hospital administered drugCRA expert, Dr. Sean Sheridan considered the Respondent’s efforts as they relate to the obligations of the licensing agreement and evaluated those efforts...View engagement
- 02Expert report, testimony in university vs biopharmaceutical companyDr. Sean Sheridan provided expert testimony on academic technology transfer practices and responded to the Plaintiff’s expert’s opinions regarding certain...View engagement
- 03Valuation of gene editing patentsCRA’s Life Sciences Practice was retained by a biotechnology company to perform a valuation of its gene editing patent portfolio, and to provide...View engagement